Filing Flows

Filing Flows › 8-K events › Sintx Technologies

Sintx Technologies: results of operations

Form 8-K filed Nov 5, 2026 · items 2.02, 7.01

FDA decisionsSINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

What the filing says

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Sintx Technologies at a glance

Latest quarterQ3 2026
Revenue$2.2M
Revenue Y/Y+953%
Operating margin-74.7%
IndustrySurgical & Medical Instruments & Apparatus

Sintx Technologies, Q3 2026: revenue $2.2M (+953% year over year), operating margin -74.7%. The chart follows the revenue to costs, profit and cash.

Sintx Technologies: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.